ClinicalTrials.gg
CompletedNCT06586294Updated Oct 16, 2026

A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

A Phase 1/2 interventional study of Drug: AK129 Drug:oxaliplatin Drug:capecitabine and Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Phase Ib/II clinical study of AK129 combined with chemotherapy with or without cadonilimab in first-line treatment of advanced HER2 negative gastric cancer or gastroesophageal junction adenocarcinoma

02

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must sign the written form(ICF) voluntarily.
  2. Aged ≥ 18 to ≤ 75 years,male and female at the time of signing the ICF.
  3. confirmed adenocarcinoma of the gastric or gastroesophageal junction (GEJ).
  4. Inoperable locally advanced or gastric or gastroesophageal junction adenocarcinoma.
  5. Participants had not previously received systemic therapy for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
  6. According to v1.1 criteria, subjects had at least one measurable tumor target.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known positive gastric or gastroesophageal junction adenocarcinoma.
  2. Histopathological examination confirmed other pathological types.
  3. Had received palliative local therapy for non-target lesions within 2 weeks before the first administration.
  4. Past treatment with ,immune checkpoint agonists,immune cell therapy and any treatment targeting the immune mechanism of tumor action.
  5. History of gastrointestinal perforation and fistula within 6 months before the first dose.
  6. Active or previously documented inflammatory bowel disease,inability to swallow, malabsorption syndrome.
  7. Active within the last 3 years.
  8. Active or untreated , meningeal , spinal cord compression, or pia meningeal disease are known to exist.
  9. The presence of clinical symptoms of pleural effusion, pericardial effusion, or abdominal effusion, or the need for frequent drainage.
  10. There was an active disease that required systemic treatment within 2 years prior to the start of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    The dose escalation and expansion stage of AK129 combined with chemotherapy;

    Part 1: The dose escalation stage# 3 dose groups of AK129 were set up, combination with chemotherapy of XELOX,followed by AK129 and capecitabine maintenance; Part 2#The dose expansion stage# Two to three dosing regimens were set for expansion of AK129 in combination with XELOX.

    Drug: Drug: AK129 Drug:oxaliplatin Drug:capecitabine

  • Experimental
    The dose escalation and expansion stage of AK129 combined with chemotherapy with cadonilimab

    Part 1:The dose escalation stage# 3 dose groups of AK129 were set up, combination with cadonilimab and chemotherapy of XELOX,followed by AK129 and cadonilimab maintenance; Part 2:The dose expansion stage# Two to three dosing regimens were set for expansion of AK129 in combination with cadonilimab and chemotherapy of XELOX.

    Drug: Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events(AE)

    Incidence and severity of AEs is aim to evaluate the safety of AK129 combined with chemotherapy with or without cadonilimab

    Time frame: Up to approximately 2 years

  2. Incidence of serious adverse events(SAE) and suspected unexpected serious adverse reactions(SUSAR)

    Incidence of SAE and SUSAR is aim to evaluate the safety of AK129 combined with chemotherapy with or without cadonilimab

    Time frame: Up to approximately 2 years

  3. Incidence of dose-limiting toxicity(DLT)

    The purpose of DLT is to find the Phase II recommended dose(RP2D) or Maximum Tolerated Dose(MTD)

    Time frame: Up to approximately 2 years

  4. Clinically significant changes in safety/laboratory evaluation parameters and AEs that led to treatment termination or suspension

    Clinically significant changes in safety/laboratory evaluation parameters and AEs that led to treatment termination or suspension is aim to evaluate the safety of AK129 combined with chemotherapy with or without cadonilimab

    Time frame: Up to approximately 2 years

  5. Objective Solution Rate (ORR) based on RECIST v1.1

    The purpose of ORR is aim to evaluate the antitumor effect,and ORR is proportion of subjects with complete response(CR) or partial response(PR), based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease control rate(DCR)

    Disease control rate(DCR) is defined as the proportion of subjects achieving a best of response(BOR) of confirmed CR or PR or stable disease(SD) per RECIST v1.1.

    Time frame: Up to approximately 2 years

  2. duration of response(DoR)

    Duration of response(DoR) is defined as the period from the first documentation of confirmed response(CR or PR) to the first documentation of progressive disease(PD) as per RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  3. time to response(TTR)

    Time to response(TTR) is defined as the time from the first dose of investigational products until the first confirmation of CR or PR.

    Time frame: Up to approximately 2 years

  4. progression-free survival(PFS)

    Progression-free survival(PFS) is defined as the time from the first dose of investigational products until documentation of progressive disease(PD) as per RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  5. overall survival(OS)

    Overall survival(OS) is defined as the time from the first dose of investigational products until death due to any cause.

    Time frame: Up to approximately 2 years

  6. Serum AK129, cadonilimab concentration, blood concentration-time curve and derived PK argument

    Serum AK129, cadonilimab concentration, blood concentration-time curve and derived PK argument to evaluate the Pharmacokinetics(PK).

    Time frame: Up to approximately 2 years

  7. Number and percentage of subjects with anti-drug antibodies (ADA) for AK129 and cadonilimab

    Number and percentage of subjects with anti-drug antibodies (ADA) for AK129 and cadonilimab will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).

    Time frame: Up to approximately 2 years

07

Study locations

1 site
  • Zhejiang Cancer Hospital
    Hanzhou, Zhejiang 310005, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2024 to primary completion in Apr 2026, 18 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jul 2026 → Apr 2026 and completion Jul 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Sep 19, 2024
StartActual
Sep 30, 2024
Primary completionActual
Apr 20, 2026was Jul 2026
CompletionActual
Apr 20, 2026was Jul 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 16, 2026
Start date
Sep 10, 2024→Sep 30, 2024 (actual)
Oct 16, 2026
Primary completion
Jul 2026→Apr 20, 2026 (actual)
Oct 16, 2026
Study completion
Jul 2026→Apr 20, 2026 (actual)
Oct 16, 2026
Enrollment
294 (estimated)→35 (actual)
Oct 16, 2026
Interventions
Changed Drug: AK129 Drug:cadonilimab Drug:oxaliplatin Drug:capecitabine→Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Completed
    Start date Sep 10, 2024→Sep 30, 2024 (now actual)
    Primary completion Jul 2026→Apr 20, 2026 (now actual)
    Study completion Jul 2026→Apr 20, 2026 (now actual)
    Enrollment 294 (estimated)→35 (actual)
    Interventions Changed Drug: AK129 Drug:cadonilimab Drug:oxaliplatin Drug:capecitabine→Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06586294
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 30, 2024
Primary completion
Apr 20, 2026
Completion
Apr 20, 2026
Last update
Oct 16, 2026

Study contacts

Xiangdong Cheng, MD
principal investigator · Zhejiang Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/LAG-3 Bispecific Antibody AK129

Start the discussion